Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Expired

Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases

National Institutes of Health

This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.

Studies conducted in various biological model systems have implicated engagement of ECS in central nervous system development, neural synaptic organization, and plasticity, and in cellular responses to injury or disease. These studies have been used as a basis for supporting the therapeutic uses of cannabis. However, conflicting clinical reports suggest both positive and negative effects of cannabinoids. As a widespread modulator system that impacts the functions of various tissues and organs, alterations in the ECS (either hypo- or hyper- activation) may disrupt molecular networks that are critical for physiological stabilization. Given these conflicting views, this NOSI encourages research to explore and validate roles of the ECS under physio-normative and disease conditions, including their sequelae, and the impacts of recreational or medicinal cannabinoid use (acute and/or chronic).

The research supported by this NOSI includes, but is not limited to: 1) research to identify the causal mechanisms underlying therapeutic benefits of cannabinoids and the ECS; 2) studies utilizing pharmacological, immunological, or genetic approaches to manipulate specific elements of the ECS; 3) research to establish biological relevance and translational validity of findings using biological models (cell/tissue, biological specimens, or postmortem brain tissue from treated or untreated SUD patients); and 4) research to investigate the role of cannabinoids and the ECS in treatment-related conditions. This NOSI also encourages research examining the longitudinal effects of cannabinoid use in order to describe biological mechanisms associated with persistent ECS dysregulation. Key in this regard is the collection of data on parameters such as dose, frequency and duration of exposure.

This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.

NOT-DA-22-048

Specialties

Medical

Medical - Clinical Science

Medical - Basic Science

Medical - Translational

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity